TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.
Brief Summary: Study N01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (LEV) versus the 2 older antiepileptic drugs (AEDs), sodium valproate extended release (VPA-ER) and carbamazepine controlled release (CBZ-CR) in the treatment of subjects with newly diagnosed epilepsy.


Options:
A: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs
B: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Arm Label: Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Lamotrigine
C: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
D: Arm Label: Carbamazepine controlled release; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eslicarbazepine acetate (BIA 2-093) | Arm Label: Eslicarbazepine acetate; Type: EXPERIMENTAL; Interventions: Drug: Eslicarbazepine acetate (BIA 2-093) | Intervention Type: DRUG; Name: Eslicarbazepine acetate (BIA 2-093); Assigned to Arm(s): Carbamazepine controlled release, Eslicarbazepine acetate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Brief Summary: This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
B: Arm Label: Brivaracetam (BRV) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam (BRV) 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Lorazepam (LZP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam (BRV) 100 mg, Brivaracetam (BRV) 200 mg | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam (LZP)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
D: Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Brief Summary: This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy


Options:
A: Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Brief Summary: This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): B
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
C: Arm Label: pregabalin CR 330 mg; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: pregabalin CR 165 mg; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 165 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 165 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 2.5 mg | Arm Label: BRV 20mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 10 mg | Arm Label: BRV 50mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 25 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam 2.5 mg; Assigned to Arm(s): Brivaracetam 5 mg/day | Intervention Type: DRUG; Name: Brivaracetam 10 mg; Assigned to Arm(s): BRV 20mg/day | Intervention Type: DRUG; Name: Brivaracetam 25 mg; Assigned to Arm(s): BRV 50mg/day

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Trial of Risperidone and Divalproex Sodium With MRI Assessment of Affected Circuitry in Pre and Post Treatment in Pediatric Bipolar
Brief Summary: The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.


Options:
A: Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: divalproex sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Divalproex Sodium (Depakote ER); Assigned to Arm(s): N/A
C: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: Divalproex sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex Sodium | Intervention Type: DRUG; Name: Divalproex Sodium; Assigned to Arm(s): Divalproex sodium | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone
D: Intervention Type: DRUG; Name: divalproex sodium; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: There is an increasing incidence of overweight children in Germany, due to a lack of physical activity.

The aim of this study is to improve physical fitness and activity in school children. Two classes in different schools are provided with additional sport lessons over a period of one year.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Active play in after school programs (ASP) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Active play in after school programs (ASP); Assigned to Arm(s): Intervention group
B: Arm Label: Peer-education Family Fitness Program; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-Education Family Fitness Program (PE-FFP) | Arm Label: Family Fitness Program (FFP); Type: OTHER; Interventions: Behavioral: Family Fitness Program (FFP) | Intervention Type: BEHAVIORAL; Name: Peer-Education Family Fitness Program (PE-FFP); Assigned to Arm(s): Peer-education Family Fitness Program | Intervention Type: BEHAVIORAL; Name: Family Fitness Program (FFP); Assigned to Arm(s): Family Fitness Program (FFP)
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cycling to school; Type: EXPERIMENTAL; Interventions: Behavioral: Cycling to school | Intervention Type: BEHAVIORAL; Name: Cycling to school; Assigned to Arm(s): Cycling to school
D: Intervention Type: BEHAVIORAL; Name: physical exercise; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: There is an increasing incidence of overweight children in Germany, due to a lack of physical activity.

The aim of this study is to improve physical fitness and activity in school children. Two classes in different schools are provided with additional sport lessons over a period of one year.


Options:
A: Intervention Type: BEHAVIORAL; Name: Diet with increased fruits, vegetables, and calcium; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased high impact activity and resistance training; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
C: Arm Label: Activity prescription; Type: EXPERIMENTAL; Interventions: Other: Activity Knowledge Circuits | Arm Label: Normal Curriculum; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Activity Knowledge Circuits; Assigned to Arm(s): Activity prescription
D: Intervention Type: BEHAVIORAL; Name: physical exercise; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: There is an increasing incidence of overweight children in Germany, due to a lack of physical activity.

The aim of this study is to improve physical fitness and activity in school children. Two classes in different schools are provided with additional sport lessons over a period of one year.


Options:
A: Arm Label: Low intensity arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary, physical activity and sleeping | Arm Label: High intensity arm; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary, physical activity and sleeping | Intervention Type: BEHAVIORAL; Name: Dietary, physical activity and sleeping; Assigned to Arm(s): High intensity arm, Low intensity arm
B: Intervention Type: BEHAVIORAL; Name: physical exercise; Assigned to Arm(s): N/A
C: Arm Label: BALANCE; Type: EXPERIMENTAL; Interventions: Behavioral: BALANCE | Intervention Type: BEHAVIORAL; Name: BALANCE; Assigned to Arm(s): BALANCE
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MOVI-KIDS Program; Type: EXPERIMENTAL; Interventions: Behavioral: MOVI-KIDS | Intervention Type: BEHAVIORAL; Name: MOVI-KIDS; Assigned to Arm(s): MOVI-KIDS Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Three Months of Aerobic Exercise Training on Exercise Capacity and Peripheral Maladaptations in Patients With Severe Chronic Heart Failure (NYHA III b)
Brief Summary: Patients with heart failure are limited in their exercise capacity due to skeletal muscle alteration and an impairment of peripheral perfusion. Regular physical exercise training has been shown to partially correct these peripheral maladaptations in patients with stable heart failure, which was associated with an improvement in exercise capacity. However, it is unknown so far, whether regular physical activity also exerts beneficial effects in patients with severe chronic heart failure.

Aim of the trial is therefore to assess the effects of aerobic exercise training on exercise capacity, muscle maladaptations and peripheral perfusion in patients with severe chronic heart failure according to NYHA class III b.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: Aerobic endurance exercise training (ergometer); Assigned to Arm(s): N/A
D: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: 12-week Tai Chi Program | Arm Label: Heart Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 12-week Education Program | Intervention Type: BEHAVIORAL; Name: 12-week Tai Chi Program; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: 12-week Education Program; Assigned to Arm(s): Heart Health Education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Three Months of Aerobic Exercise Training on Exercise Capacity and Peripheral Maladaptations in Patients With Severe Chronic Heart Failure (NYHA III b)
Brief Summary: Patients with heart failure are limited in their exercise capacity due to skeletal muscle alteration and an impairment of peripheral perfusion. Regular physical exercise training has been shown to partially correct these peripheral maladaptations in patients with stable heart failure, which was associated with an improvement in exercise capacity. However, it is unknown so far, whether regular physical activity also exerts beneficial effects in patients with severe chronic heart failure.

Aim of the trial is therefore to assess the effects of aerobic exercise training on exercise capacity, muscle maladaptations and peripheral perfusion in patients with severe chronic heart failure according to NYHA class III b.


Options:
A: Arm Label: No intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): No intervention | Intervention Type: BEHAVIORAL; Name: Rehabilitation intervention; Assigned to Arm(s): Active Comparator
B: Intervention Type: BEHAVIORAL; Name: Aerobic endurance exercise training (ergometer); Assigned to Arm(s): N/A
C: Arm Label: Walking intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking intervention; Assigned to Arm(s): Walking intervention
D: Arm Label: Walking intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking intervention; Assigned to Arm(s): Walking intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia
Brief Summary: The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.


Options:
A: Arm Label: galantamine; Type: EXPERIMENTAL; Interventions: Drug: galantamine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: galantamine | Intervention Type: DRUG; Name: galantamine; Assigned to Arm(s): galantamine, placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
C: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Bupropion SR and Placebo for Smoking Cessation
Brief Summary: The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of successful abstinence in this population. If bupropion SR is effective for reducing cigarette smoking, then it will be important to determine if decreased nicotine intake is associated with a worsening of psychotic, anxiety or depressive symptoms. In addition, it would be important to determine the effect that a reduction in nicotine stimulation would have on patient's cognitive functioning, as nicotinic receptors have been shown to regulate attention and memory function, and it is hypothesized that these functions are normalized by acute nicotine administration in people with schizophrenia


Options:
A: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo

Answer: D